JPRN-UMIN000001408已完成2 期
A Phase II Study of Trastuzumab plus S-1 in Patients with Advanced or Recurrent HER2 positive Breast Cancer - A Phase II Study of Trastuzumab plus S-1 in Patients with Advanced or Recurrent HER2 positive Breast Cancer
Gunma Breast Clinical Conference Study Group(GBCCSG)0 个研究点目标入组 30 人开始时间: 2008年10月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Male breast cancer 2) Necessary to continue treatment with warfarin potassium 3) Severe complications [ulcer which needs blood transfusion, uncontrolled diabetes mellitus, interstitial lung disease, pulmonary fibrosis, cerebral thrombosis, cerebral hemorrhage, subarachnoid hemorrhage, ischemia attack, encephalosis, stenocardia, myocardial infarction, uncontrolled congestive heart failure or arrhythmia, intestinal tract paralysis, ileus, neurodegeneration disease, hepatic insufficiency, cirrhosis, renal insufficiency] 4) Active double cancer 5) Inflammatory breast cancer or symptomatic brain metastasis 6) Patients who have only the lesion which caught the radiation exposure 7) Patients who received previous treatment with oral fluoropyrimidines within 12 months 8) internal use of flucytosyne 9) doctors decision for excluion
研究者
相似试验
已完成
2 期
A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2 positive advanced gastric cancergastric cancerJPRN-UMIN000017602Cancer Institute Hospital Japanese Foundation For Cancer Research75
已完成
2 期
Phase II trial of TS-1 plus Trastuzumab in patients with metastatic breast cancerbreast cancerJPRN-UMIN000004764Tokai University School of Medicine30
招募中
不适用
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancerNeoplasmsKCT0004391Asan Medical Center28
招募中
2 期
Phase II single-arm study of Trastuzumab combination with Cisplatin and Gemcitabine as first-line therapy in the HER-2 positive Advanced CholangioCArcinomaAdvanced biliary tract cancersHER-2 positiveFirst-line therapyGallbladder CancerBiliary Tract CancersOncogene Protein HER-2TrastuzumabCisplatinGemcitabineCancer Chemotherapy AgentCombined Antineoplastic AgentsCholangiocarcinomaTCTR20220328005Khon Kaen University33
已完成
1 期
A Phase Ib study of Trastuzumab emtansine plus S-1 or Capecitabine in patients with previously trastuzumab treated metastatic breast cancerPatients with HER2-positive metastatic breast cancer that has progressed on trastuzumabJPRN-UMIN000018383St Marianna University School of Medicine20